Therapeutic Breakthroughs Come from Breaking Barriers

Founded in 2017 by Flagship Pioneering, Cygnal Therapeutics is the first company to build a platform to develop drugs in the field of exoneural biology. Exoneural biology is broadly implicated in human health and disease. Fueled by our dynamic Exoneural Medicine Platform™, we are creating new medicines across multiple therapeutic areas, starting with cancer and inflammatory diseases.

Cygnal is a best-in-class team of biomedical experts and leaders collaborating to revolutionize how the world treats diseases.